Document


 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 19, 2017
 
OPHTHOTECH CORPORATION
(Exact Name of Registrant as Specified in Charter)
 
Delaware
 
001-36080
 
20-8185347
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
One Penn Plaza, 19th Floor
New York, New York 10119
(Address of Principal Executive Offices) (Zip Code)
 
Registrant’s telephone number, including area code: (212) 845-8200
 
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 

 




Item 5.07.  Submission of Matters to a Vote of Security Holders.
 
Ophthotech held its Annual Meeting of Stockholders on May 19, 2017. The following is a summary of the matters voted on at that meeting.
 
(a)         Ophthotech’s stockholders elected Michael Ross, Ph.D. and Glenn P. Sblendorio as Class I directors to serve until the 2020 Annual Meeting of Stockholders, each such director to hold office until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:
 
 
 
For
 
Withheld
 
Broker
Non-Votes
 
Michael Ross, Ph.D.
 
16,330,286
 
819,537
 
11,361,105
 
Glenn P. Sblendorio
 
14,974,194
 
2,175,629
 
11,361,105
 
         
(b)         Ophthotech’s stockholders approved a non-binding, advisory proposal on the compensation of Ophthotech’s named executive officers. The results of the stockholders’ vote with respect to such matter were as follows:

For
 
Against
 
Abstain
 
Broker
Non-Votes
 
10,982,939
 
6,109,509
 
57,375
 
11,361,105
 

(c)         Ophthotech’s stockholders ratified the selection of Ernst & Young LLP as Ophthotech’s independent registered public accounting firm for the current fiscal year. The results of the stockholders’ vote with respect to such matter were as follows:
 
For
 
Against
 
Abstain
 
Broker
Non-Votes
 
27,542,577
 
755,300
 
213,051
 
0
 



2




 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
OPHTHOTECH CORPORATION
 
 
Date: May 22, 2017
By:
/s/ Barbara A. Wood
 
 
Barbara A. Wood
 
 
Senior Vice President, General Counsel and Secretary
 
3